Autobio Diagnostics Co

Autobio Diagnostics Co Net Debt

The Net Debt of Autobio Diagnostics Co (603658.SS) as of Oct 20, 2026 is -3.79 B CNY. In the previous year, Net Debt was -4.15 B CNY — a change of -8.74% (higher).

Net Debt

-3.79 BCNY

YoY

-8.74%

Last updated:

Net Debt of Autobio Diagnostics Co is 2024 -3.79 B CNY. Net Debt of Autobio Diagnostics Co was 2023 -4.15 B CNY. It decreases by -8.74% higher compared to the previous year.

The Autobio Diagnostics Co Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
12.06 M CNY
Jan 1, 2018
38.35 M CNY
Jan 1, 2019
537.84 M CNY
Jan 1, 2020
-213.30 M CNY
Jan 1, 2021
-540.66 M CNY
Jan 1, 2022
-1.01 B CNY
Jan 1, 2023
-4.15 B CNY
Jan 1, 2024
-3.79 B CNY
The Autobio Diagnostics Co Net Debt history
YEARNet DebtYoY
-3.79 BCNY-8.74%
-4.15 BCNY+313.16%
-1.01 BCNY+85.90%
-540.66 MCNY+153.48%
-213.30 MCNY-139.66%
537.84 MCNY+1,302.49%
38.35 MCNY+217.86%
12.06 MCNY-112.00%
-100.53 MCNY+25.42%
-80.15 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Autobio Diagnostics Co Stock analysis

What does Autobio Diagnostics Co do? Autobio Diagnostics Co., Ltd. generates revenue through the sale of in vitro diagnostic reagents and instruments, including gnostic products, microbiology detection products, and related devices. The company's immunodiagnostic products consist of microplate chemiluminescence diagnostic reagents, Enzyme-Linked immunosorbent assay diagnostic reagents, magnetic particle chemiluminescence detection reagents, and colloidal diagnostic reagents. Microbiology detection products feature training detection reagents, susceptibility detection reagents, and rapid detection reagents. Device products include microplate readers, chemiluminescence immunoassay analyzers, and united testing analyzers, all distributed within domestic markets. The firm targets domestic healthcare providers and laboratories as primary buyers of its diagnostic reagents and instruments. Its core products serve clinical diagnostics needs for infectious disease testing, microbial identification, and immune response analysis. The company's product portfolio emphasizes domestic market distribution, with no mention of international sales channels or export activities. Autobio Diagnostics' revenue streams are derived from the manufacturing and distribution of diagnostic reagents, instruments, and related devices. The company focuses on domestic market penetration through its product range, which includes specialized reagents for microbiology and immunodiagnosis. No additional revenue sources such as service contracts or software licensing are indicated in the business description. Autobio Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Autobio Diagnostics Co stock

Net Debt of Autobio Diagnostics Co is -3.79 B CNY in 2024.

Net Debt of Autobio Diagnostics Co changed from -4.15 B CNY to -3.79 B CNY, representing a -8.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Autobio Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Autobio Diagnostics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Autobio Diagnostics Co

All Key Metrics — Autobio Diagnostics Co